J&J Gene Therapy Treatment For Vision Loss Fails to Meet Primary Endpoints
Johnson & Johnson acquired the entire rights to a gene treatment for a rare condition some years ago; the pharmaceutical giant may now be going through buyer’s remorse. The therapy did not enhance...
View ArticleNew Data Positions Immutep’s Immunotherapy Combo as First-Line Option for...
Immutep, the developer of eftilagimod alpha, has reported promising overall survival (OS) results that could pave the way for regulatory approval in first-line head and neck cancer treatment. In a...
View ArticleEli Lilly Secures Rights to Alchemab’s Early-Stage ALS Drug in $415M Deal
Just four months after announcing a research collaboration, Eli Lilly is licensing its first drug candidate from British biotech Alchemab. The agreement, valued at up to $415M, includes a combination...
View ArticleVertex Presses Pause on CF Study, Reports Major Write-Down
Vertex Pharmaceuticals has announced a temporary pause in part of a clinical trial evaluating its cystic fibrosis (CF) candidate, VX-522, due to a tolerability concern. The update was included in the...
View ArticleFDA Clears First At-Home HPV and Cervical Cancer Screening Kit
The U.S. Food and Drug Administration has approved the first at-home collection kit designed to allow women to screen themselves for human papillomavirus (HPV) and assess cervical cancer risk using a...
View ArticleEli Lilly Invests $250 Million to Strengthen Ties with Purdue University
Eli Lilly is deepening its investment in Indiana by committing up to $250 million over the next eight years to expand its existing collaboration with Purdue University. According to a press release,...
View ArticleFDA and CDC Recommend Halting Chikungunya Vaccine Use in Older Adults
Following similar actions by France and the European Union, U.S. health authorities are urging a pause in the use of Valneva’s chikungunya vaccine, Ixchiq, in older adults. The U.S. Food and Drug...
View ArticleAbeona Nets $155M in Voucher Sale After FDA Approval
Abeona Therapeutics has secured a $155 million deal from the sale of a Priority Review Voucher (PRV), just two weeks after receiving U.S. Food and Drug Administration (FDA) approval for its first...
View ArticleLife Sciences Voice Top Five Newsletter
Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthroughs in the life sciences industry! This time, we’re looking at Eli Lilly’s $250...
View ArticlePathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered...
Pathos AI, a clinical-stage biotech company leveraging artificial intelligence to revolutionize cancer treatment, has announced the successful close of a $365 million Series D funding round. The...
View ArticleFDA Delays Biohaven’s Approval Decision for Rare Disease Drug Troriluzole
The U.S. Food and Drug Administration (FDA) has postponed its decision on Biohaven Pharmaceuticals’ lead drug candidate, troriluzole, a potential treatment for a group of rare neurological conditions...
View ArticleFDA Sets Tougher Approval Criteria for Covid Booster Shots in Healthy...
The Food and Drug Administration (FDA) has introduced more rigorous regulatory requirements for approving future COVID-19 booster shots, particularly for healthy individuals. This marks a significant...
View ArticleBoehringer’s Nerandomilast Advances in IPF Amid Analyst Reservations
Boehringer Ingelheim’s presentation of phase 3 data for its idiopathic pulmonary fibrosis (IPF) drug candidate nerandomilast has received a reserved response from analysts, who described the treatment...
View ArticleCellCentric Secures $120M Series C Funding to Advance Myeloma Drug Inobrodib
CellCentric, a UK-based biotechnology company backed by Pfizer, has raised $120 million in Series C funding to accelerate the development of its first-in-class multiple myeloma treatment, inobrodib....
View ArticleScientists Identify New Target to Prevent Cancer from Spreading to Bones
In a major breakthrough, researchers have uncovered a potential way to stop cancer from spreading to the bones—a painful and common complication in many cancer patients. Using CRISPR gene-editing...
View ArticleModerna Delays Flu-COVID Combo Vaccine Filing Amid FDA Request
Moderna has announced that it is withdrawing its application for approval from the U.S. Food and Drug Administration (FDA) for its combination flu and COVID-19 vaccine, identified as mRNA-1083....
View ArticleSanofi Acquires Vigil Neuroscience for $470M to Boost Alzheimer’s Drug Pipeline
Sanofi is acquiring Vigil Neuroscience for $470 million to expand its Alzheimer’s drug portfolio, focusing on TREM2-targeting therapies like VG-3927. Learn how this acquisition strengthens Sanofi’s...
View ArticleGilead Secures Arenavirus Vaccine Programs from Hookipa for $10 Million
Gilead Sciences has acquired exclusive ownership of two arenavirus-based immunotherapy programs for hepatitis B (HBV) and human immunodeficiency virus (HIV) from Hookipa Pharma. The transaction is the...
View ArticleMixed Results in COPD Trials Cast Doubt on Approval for Sanofi, Regeneron’s...
Sanofi and Regeneron’s experimental COPD drug, itepekimab, produced mixed results in two Phase 3 trials, raising serious questions about its chances of regulatory approval. While one of the late-stage...
View ArticleAkeso, Summit’s Antibody Shows Promise in Phase 3 Trials
In its inaugural worldwide phase 3 results, the PD-1xVEGF bispecific antibody ivonescimab, developed by Akeso and Summit Therapeutics, decreased the probability of progression or death by 48% among...
View Article